+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Pruritus Therapeutics Market by Therapy, Route of Administration, Disease Indication, Patient Demographics, Distribution Channel, End-User - Global Forecast to 2030

  • PDF Icon

    Report

  • 186 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5888867
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Pruritus Therapeutics Market grew from USD 5.93 billion in 2024 to USD 6.24 billion in 2025. It is expected to continue growing at a CAGR of 5.47%, reaching USD 8.17 billion by 2030.

Navigating the Pruritus Therapeutics Frontier

Pruritus, commonly known as chronic itching, poses a significant clinical burden affecting millions of patients worldwide. This executive summary delves into the multifaceted landscape of pruritus therapeutics, exploring current treatment modalities, emerging innovations, and shifting market dynamics. As global healthcare systems grapple with increasing patient demand and evolving regulatory environments, stakeholders must understand the interplay between scientific advancements and commercial realities.

This introduction establishes a foundation for the subsequent sections by outlining the scope of the analysis, the key drivers shaping therapeutic development, and the strategic importance of targeted interventions. By examining the latest breakthroughs in pharmacology alongside broader healthcare trends, this summary equips decision-makers with the context necessary to navigate the competitive terrain. The goal is to illuminate opportunities for investment, partnership, and product differentiation within a market marked by rapid progress and complex challenges.

Key Forces Redefining Industry Dynamics

The pruritus therapeutics landscape is undergoing transformative shifts fueled by technological advances and evolving patient expectations. Precision medicine is emerging as a cornerstone, enabling the development of biologic therapies that target specific inflammatory pathways responsible for chronic itching. Traditional antihistamines and corticosteroids are now being supplemented with novel monoclonal antibodies and small molecule inhibitors, reflecting a broader trend toward personalized treatment regimens.

At the same time, digital health solutions and telemedicine platforms are enhancing patient engagement and adherence. Remote monitoring tools provide real-time feedback on symptom progression, while artificial intelligence algorithms analyze patient data to recommend optimized dosing schedules. These innovations not only improve clinical outcomes but also create new channels for market differentiation. Consequently, companies that integrate digital and therapeutic solutions stand to gain a competitive edge as the market transitions from one-size-fits-all approaches toward individualized care.

Assessing the Ripple Effect of 2025 US Tariffs

In 2025, the implementation of revised United States tariffs is poised to exert a noticeable impact on the cost structure of pruritus therapeutics. Higher duties on raw materials and active pharmaceutical ingredients have introduced additional pressure on manufacturers’ margins, leading to price adjustments across the supply chain. Healthcare providers and payers are bracing for potential budgetary reallocations as procurement costs rise.

Pharmaceutical companies are responding through strategic sourcing initiatives and increased localization of production facilities to mitigate tariff-related expenses. Some organizations are negotiating long-term supply agreements to lock in favorable pricing, while others are exploring partnerships with domestic suppliers to reduce reliance on imported inputs. These proactive measures are essential to preserving product affordability and maintaining market share in a tariff-sensitive environment.

Unveiling Insights Across Critical Market Segments

An in-depth examination of market segmentation reveals distinct patterns of demand and growth potential across therapy classes, routes of administration, disease indications, patient demographics, distribution channels, and end-user settings. Antihistamines and corticosteroids continue to anchor the market, while biologics and immunosuppressants gain traction among patients with moderate to severe conditions. Calcineurin inhibitors occupy a niche role in specialty care, reflecting their targeted immunomodulatory effects.

By administration method, injectable therapies dominate in hospital and dermatology centers due to clinician-administered protocols, whereas oral and topical formulations enjoy broad adoption in outpatient and homecare contexts. Allergic contact dermatitis and atopic dermatitis remain the primary indications driving volume, but growing awareness of cutaneous T-cell lymphoma and chronic urticaria is expanding the scope of treatment pipelines. Adult patients account for the largest segment by patient demographic, yet pediatric and geriatric populations display unique needs that spur demand for age-appropriate formulations and delivery systems.

Hospital pharmacies lead distribution of high-cost biologics and injectables, while retail and online pharmacies cater to long-term therapies in chronic cases. Clinics and homecare settings are emerging as significant end-user channels, particularly for topical and oral products, as patients seek convenient, outpatient management of symptoms. Dermatology centers maintain a central role in advancing specialty treatments and facilitating clinical trials, ensuring that innovation continues to flow from research labs to point-of-care environments.

Regional Variations Driving Targeted Strategies

Regional analysis underscores the diversity of market dynamics and highlights tailored strategies for success in each key geography. In the Americas, robust healthcare infrastructure and well-established reimbursement frameworks support rapid adoption of premium-priced biologics and advanced therapies. Patient advocacy groups and clinical societies in this region actively drive awareness campaigns, influencing prescribing patterns and accelerating market uptake of novel treatments.

Europe, Middle East & Africa present a mosaic of market maturity levels and regulatory approaches. Western European markets demonstrate high therapeutic penetration, whereas emerging economies in Eastern Europe, the Middle East, and Africa exhibit untapped potential, constrained by variable access to healthcare and differing approval timelines. Stakeholders aiming to expand in these territories must navigate complex reimbursement negotiations and engage local partners to address supply chain and distribution challenges.

In Asia-Pacific, a combination of rising healthcare expenditure, expanding insurance coverage, and growing interest in personalized medicine is reshaping the pruritus landscape. Key markets such as Japan and Australia show strong demand for next-generation therapies, while China and India present scale opportunities driven by large patient populations. Market entrants must adapt pricing and engagement models to reflect regional diversity, balancing high-value offerings with affordability initiatives to capture share across a spectrum of healthcare environments.

Competitive Landscape and Strategic Positioning

The competitive landscape features a blend of established pharmaceutical giants and emerging biotech innovators. Long-standing market leaders maintain dominance through broad portfolios spanning antihistamines, corticosteroids, and calcineurin inhibitors, backed by deep commercial networks and strong brand recognition. At the same time, specialized firms have gained prominence by advancing biologics and novel small molecule therapies tailored to specific immune pathways.

Strategic partnerships and licensing agreements have become common vehicles for pipeline expansion, enabling companies to access complementary technologies and expedite time to market. Mergers and acquisitions further shape the terrain, consolidating capabilities in research, manufacturing, and distribution. As a result, agility and collaborative prowess are increasingly critical success factors. Organizations that harness external innovation while reinforcing core competencies position themselves to thrive amid accelerating change.

Strategic Imperatives for Market Leadership

Industry leaders must embrace a multifaceted strategy that balances innovation, access, and operational efficiency. First, prioritizing the development of targeted biologics and non-steroidal small molecules can differentiate portfolios and address unmet needs in severe pruritus. Second, integrating digital health solutions into patient support programs will bolster adherence and provide real-world evidence to strengthen payer engagement. Third, optimizing supply chains through strategic sourcing and localized manufacturing will mitigate tariff and logistics pressures, safeguarding margins.

Continued investment in clinical research collaborations and real-world data initiatives will reinforce evidence generation and underpin regulatory submissions. To enhance market penetration, companies should tailor launch strategies to regional nuances, leveraging local partnerships to navigate reimbursement landscapes and foster prescriber relationships. By adopting this comprehensive approach, industry players can sustain momentum, capitalize on emerging trends, and deliver meaningful outcomes for patients and stakeholders alike.

Robust Methodology Underpinning Our Analysis

Our analysis draws upon a structured methodology that combines primary qualitative interviews with key opinion leaders, regulatory experts, and commercial executives, alongside secondary research from peer-reviewed journals, industry reports, and proprietary databases. We conducted rigorous data triangulation to validate insights, ensuring a balanced perspective on market drivers, restraints, and competitive dynamics.

Proprietary frameworks guided our evaluation of technology readiness levels and therapeutic potential, while financial modeling assessed cost impacts under various tariff scenarios. Geographic market assessments incorporated macroeconomic indicators, healthcare expenditure trends, and policy landscapes. This multi-layered approach ensures that the findings presented are robust, reliable, and relevant to strategic decision-making in the pruritus therapeutics sector.

Synthesizing Insights for Informed Decision Making

In synthesizing the insights presented, this executive summary offers a comprehensive view of the pruritus therapeutics market as it stands at a pivotal juncture. The interplay of scientific innovation, regulatory shifts, and economic pressures creates both challenges and opportunities for stakeholders across the value chain. Recognizing the importance of targeted therapies, digital integration, and agile operations will be essential for sustainable growth.

As the market continues to evolve, ongoing vigilance regarding policy changes, clinical advancements, and competitive movements will inform optimal resource allocation and strategic direction. By leveraging the insights and recommendations provided here, decision-makers can chart a course toward improved patient outcomes, enhanced market access, and long-term commercial success.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Therapy
    • Antihistamines
    • Biologics
    • Calcineurin inhibitors
    • Corticosteroids
    • Immunosuppressant
  • Route of Administration
    • Injectable
    • Oral
    • Topical
  • Disease Indication
    • Allergic Contact Dermatitis
    • Atopic Dermatitis
    • Cutaneous T-cell
    • Urticaria
  • Patient Demographics
    • Adult Patients
    • Geriatric Patients
    • Pediatric Patients
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • End-User
    • Clinics
    • Dermatology Centers
    • Homecare Settings
    • Hospitals
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • AbbVie Inc.
  • Asana BioSciences, LLC
  • Astellas Pharma Inc.
  • Avior Bio Inc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Cara Therapeutics Inc.
  • Eli Lilly and Company
  • EPI Health LLC by Novan, Inc.
  • Escient Pharmaceuticals by Incyte Corporation
  • Evelo Biosciences, Inc.
  • Galderma S.A.
  • GlaxoSmithKline plc
  • LEO Pharma A/S
  • Mallinckrodt plc
  • MC2 Therapeutics A/S
  • Mirum Pharmaceuticals, Inc.
  • NeRRe Therapeutics Ltd
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Toray Industries, Inc.
  • Trevi Therapeutics, Inc
  • Vanda Pharmaceuticals Inc.
  • Viatris Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Pruritus Therapeutics Market, by Therapy
8.1. Introduction
8.2. Antihistamines
8.3. Biologics
8.4. Calcineurin inhibitors
8.5. Corticosteroids
8.6. Immunosuppressant
9. Pruritus Therapeutics Market, by Route of Administration
9.1. Introduction
9.2. Injectable
9.3. Oral
9.4. Topical
10. Pruritus Therapeutics Market, by Disease Indication
10.1. Introduction
10.2. Allergic Contact Dermatitis
10.3. Atopic Dermatitis
10.4. Cutaneous T-cell
10.5. Urticaria
11. Pruritus Therapeutics Market, by Patient Demographics
11.1. Introduction
11.2. Adult Patients
11.3. Geriatric Patients
11.4. Pediatric Patients
12. Pruritus Therapeutics Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
13. Pruritus Therapeutics Market, by End-User
13.1. Introduction
13.2. Clinics
13.3. Dermatology Centers
13.4. Homecare Settings
13.5. Hospitals
14. Americas Pruritus Therapeutics Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Pruritus Therapeutics Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Pruritus Therapeutics Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. AbbVie Inc.
17.3.2. Asana BioSciences, LLC
17.3.3. Astellas Pharma Inc.
17.3.4. Avior Bio Inc.
17.3.5. Bausch Health Companies Inc.
17.3.6. Bayer AG
17.3.7. Cara Therapeutics Inc.
17.3.8. Eli Lilly and Company
17.3.9. EPI Health LLC by Novan, Inc.
17.3.10. Escient Pharmaceuticals by Incyte Corporation
17.3.11. Evelo Biosciences, Inc.
17.3.12. Galderma S.A.
17.3.13. GlaxoSmithKline plc
17.3.14. LEO Pharma A/S
17.3.15. Mallinckrodt plc
17.3.16. MC2 Therapeutics A/S
17.3.17. Mirum Pharmaceuticals, Inc.
17.3.18. NeRRe Therapeutics Ltd
17.3.19. Novartis AG
17.3.20. Pfizer Inc.
17.3.21. Regeneron Pharmaceuticals, Inc.
17.3.22. Sanofi S.A.
17.3.23. Teva Pharmaceutical Industries Ltd.
17.3.24. Toray Industries, Inc.
17.3.25. Trevi Therapeutics, Inc
17.3.26. Vanda Pharmaceuticals Inc.
17.3.27. Viatris Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. PRURITUS THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. PRURITUS THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. PRURITUS THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. PRURITUS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. PRURITUS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. PRURITUS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ALLERGIC CONTACT DERMATITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ATOPIC DERMATITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY CUTANEOUS T-CELL, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY URTICARIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DERMATOLOGY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 48. CANADA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 49. CANADA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. CANADA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 51. CANADA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 52. CANADA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. CANADA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 54. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 55. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 57. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 58. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 72. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 73. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 75. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 79. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 80. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 82. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 83. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 85. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 86. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 88. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 89. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 91. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 92. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 94. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 95. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 97. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 98. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 100. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 101. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 103. ITALY PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 104. ITALY PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 105. ITALY PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 106. ITALY PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 107. ITALY PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. ITALY PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 109. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 110. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 112. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 113. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 115. UNITED ARAB EMIRATES PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 116. UNITED ARAB EMIRATES PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. UNITED ARAB EMIRATES PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 118. UNITED ARAB EMIRATES PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 119. UNITED ARAB EMIRATES PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. UNITED ARAB EMIRATES PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. SAUDI ARABIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 124. SAUDI ARABIA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 125. SAUDI ARABIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. SAUDI ARABIA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 127. SOUTH AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 128. SOUTH AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. SOUTH AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 130. SOUTH AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 131. SOUTH AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. SOUTH AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 133. DENMARK PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 134. DENMARK PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. DENMARK PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 136. DENMARK PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 137. DENMARK PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. DENMARK PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 139. NETHERLANDS PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 140. NETHERLANDS PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. NETHERLANDS PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 142. NETHERLANDS PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 143. NETHERLANDS PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. NETHERLANDS PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 145. QATAR PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 146. QATAR PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. QATAR PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 148. QATAR PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 149. QATAR PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. QATAR PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 151. FINLAND PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 152. FINLAND PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. FINLAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 154. FINLAND PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 155. FINLAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. FINLAND PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 157. SWEDEN PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 158. SWEDEN PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 159. SWEDEN PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 160. SWEDEN PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 161. SWEDEN PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. SWEDEN PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 163. NIGERIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 164. NIGERIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. NIGERIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 166. NIGERIA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 167. NIGERIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 168. NIGERIA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 169. EGYPT PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 170. EGYPT PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 171. EGYPT PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 172. EGYPT PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 173. EGYPT PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. EGYPT PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 175. TURKEY PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 176. TURKEY PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 177. TURKEY PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 178. TURKEY PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 179. TURKEY PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. TURKEY PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 181. ISRAEL PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 182. ISRAEL PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. ISRAEL PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 184. ISRAEL PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 185. ISRAEL PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. ISRAEL PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 187. NORWAY PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 188. NORWAY PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. NORWAY PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 190. NORWAY PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 191. NORWAY PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. NORWAY PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 193. POLAND PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 194. POLAND PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 195. POLAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 196. POLAND PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 197. POLAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. POLAND PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 199. SWITZERLAND PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 200. SWITZERLAND PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 201. SWITZERLAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 202. SWITZERLAND PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 203. SWITZERLAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. SWITZERLAND PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 205. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 206. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 207. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 208. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 209. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 210. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 211. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 212. CHINA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 213. CHINA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. CHINA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 215. CHINA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 216. CHINA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. CHINA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 218. INDIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 219. INDIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. INDIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 221. INDIA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 222. INDIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 223. INDIA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 224. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 225. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 226. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 227. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 228. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 230. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 231. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 232. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 233. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 234. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 236. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 237. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 238. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 239. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 240. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 241. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 242. INDONESIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 243. INDONESIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. INDONESIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 245. INDONESIA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 246. INDONESIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 247. INDONESIA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 248. THAILAND PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 249. THAILAND PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 250. THAILAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 251. THAILAND PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 252. THAILAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 253. THAILAND PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 254. PHILIPPINES PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 255. PHILIPPINES PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 256. PHILIPPINES PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 257. PHILIPPINES PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 258. PHILIPPINES PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 259. PHILIPPINES PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 260. MALAYSIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 261. MALAYSIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 262. MALAYSIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 263. MALAYSIA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 264. MALAYSIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 265. MALAYSIA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 266. SINGAPORE PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 267. SINGAPORE PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. SINGAPORE PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 269. SINGAPORE PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 270. SINGAPORE PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. SINGAPORE PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 272. VIETNAM PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 273. VIETNAM PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 274. VIETNAM PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 275. VIETNAM PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 276. VIETNAM PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 277. VIETNAM PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 278. TAIWAN PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 279. TAIWAN PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 280. TAIWAN PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 281. TAIWAN PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 282. TAIWAN PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 283. TAIWAN PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 284. PRURITUS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
TABLE 285. PRURITUS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Pruritus Therapeutics market report include:
  • AbbVie Inc.
  • Asana BioSciences, LLC
  • Astellas Pharma Inc.
  • Avior Bio Inc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Cara Therapeutics Inc.
  • Eli Lilly and Company
  • EPI Health LLC by Novan, Inc.
  • Escient Pharmaceuticals by Incyte Corporation
  • Evelo Biosciences, Inc.
  • Galderma S.A.
  • GlaxoSmithKline plc
  • LEO Pharma A/S
  • Mallinckrodt plc
  • MC2 Therapeutics A/S
  • Mirum Pharmaceuticals, Inc.
  • NeRRe Therapeutics Ltd
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Toray Industries, Inc.
  • Trevi Therapeutics, Inc
  • Vanda Pharmaceuticals Inc.
  • Viatris Inc.

Table Information